During a live virtual event, Jason Westin, MD, discussed the challenges of giving patients access to chimeric antigen receptor T-cell therapy.
DISCUSSION QUESTIONS
JASON WESTIN, MD: Let’s talk about the real-world challenges with CAR T-cell therapy in the community setting, things we just mentioned: access, cost, cell collection, and length of hospital stay. Dr Hasanov, what is your access to CAR T-cell therapy, and how feasible, logistically, is it for your patients to gain access?
ELSHAD HASANOV, MD: I’m a medical oncology fellow at [The University of Texas] MD Anderson Cancer Center. At MD Anderson, [we have access], but in the MD Anderson oncology program at Lyndon B. Johnson [LBJ] Hospital, it’s a bit challenging. So, it’s hard for me to answer the questions for either of the sites. But it’s basically not possible for those patients at the LBJ Hospital site.
WESTIN: Outside of the auspices of MD Anderson, how does that work? Like you said, there are situations where you can potentially see a CAR T-cell therapy center from your back door but may not be able to get there, in terms of logistical access. Dr Malik, have you had an opportunity to refer for a patient for CAR T-cell therapy?
HENNA MALIK, MD: I’m in community practice at Texas Oncology in Houston. So, I’m not too far from MD Anderson, it’s just running the logistics and seeing the performance status of the patient, how strong they are. That’s usually what hinders us getting them down to autologous SCT or to CAR T-cell therapy. It also depends on their insurance plan, because a lot of the plans Texas Oncology takes, MD Anderson doesn’t accept. So, that’s also a hindrance for these patients. So, it just depends on their insurance and their performance status. I haven’t had a patient yet that I’ve referred, just because they’ve been too weak around third-line treatment to be evaluated for CAR T cell.
WESTIN: I think there is a Goldilocks pattern here, where you have to get a patient before they’re too sick, but obviously you can’t send them when they’re [in perfect shape]. It’s making sure that you’re getting access at a time point that’s relevant for the patient. Dr Anderlini performs the apheresis procedure for a lot of these patients. But, Dr Anderlini, I know you know the data quite well for CAR T-cell therapy compared with other options. In our transplant department, we’re believers in cell therapy. But how do you view CAR T-cell therapy fitting into the regimens for second-line and third-line patients with large-cell lymphoma?
PAOLO ANDERLINI, MD: As you pointed out, I have somewhat of a skewed point of view here, because working at MD Anderson, we have access to CAR T-cell therapy. But as a transplanter, however, I think it’s going to be some brainstorming and serious thinking after physicians look at the plenary session at the American Society of Hematology 2021 Annual Meeting with the primary analysis of the ZUMA-7 trial [NCT03391466]. The results suggest comparing CAR T-cell therapy versus standard-of-care therapy, including SCT. So I think that there may be some second thoughts as far as whether CAR T-cell therapy should be considered or not.
WESTIN: Dr Obi-Anyadike, what’s been your experience with the CAR T-cell therapy, in terms of referring your patients, and how has that fit into your practice?
GLORIA OBI-ANYADIKE, PHD: I’m in an academic, transplant, and CAR-T therapy center. So, we do offer a variety of CAR T-cell therapies for DLBCL. For the most part, it’s been good experience in terms of some of these patients doing very well with CAR T-cell therapy, and then some don’t. It just depends on the refractoriness of the disease you’re dealing with.
WESTIN: Since you have the personal experience with CAR T-cell therapy, is there a group, or a type of patient, that you would not want to take to CAR T-cell therapy? Is there a red flag for a situation when you would say CAR T cell is not a good idea?
OBI-ANYADIKE: I think, for the most part, even your 80- to 82-year-old patients do very well with CAR T-cell therapy versus SCT, unless you have a patient with a severe chronic disease—maybe on dialysis—or you have a patient that has a history of stroke, and/or neurological deficit. But, for the most part, it’s pretty well tolerated, other than getting them the lymphodepletion chemotherapy, and then infusion, and then supportive care as they recover from the therapy.
WESTIN: I agree. In our practice at MD Anderson, we take a lot of patients who are borderline candidates for aggressive therapies like SCT to CAR T-cell therapy. I think our eldest person that I’m aware of is 89 years old, but a very fit 89-year-old, not somebody who’s bedbound and had a heart attack last week. These are relatively fit patients for their age, and they can tolerate it well. They don’t always respond to the CAR T cells, of course, but there is at least intention to treat there. But it’s difficult. Sometimes patients that have medical comorbidities; as Dr Lee mentioned, performance status can sometimes be a rate-limiting step. Dr Obi-Anyadike said dialysis it can be a problem. So, certainly there’s reasons why we may not be able to go for CAR T cell therapy.
Challenges for Non–CAR T-Cell Treatment of Early Relapsed DLBCL
April 18th 2024During a Case-Based Roundtable® event, Elizabeth A. Brém, MD, discussed treatment approaches for a patient with early relapsed or primary refractory diffuse large B-cell lymphoma in the first article of a 2-part series.
Read More
Retrospective Data Demonstrates Efficacy of Regorafenib in mCRC
April 16th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
Glofitamab Plus Chemo Improves Survival vs Rituximab in R/R DLBCL
April 16th 2024The phase 3 STARGLO trial met its primary end point, improving overall survival in patients with relapsed/refractory diffuse large B-cell lymphoma with glofitamab and chemotherapy vs rituximab and chemotherapy.
Read More
Long-Term Ipi/Nivo RCC Data Show Durability Across Risk Groups
April 12th 2024During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the 8-year follow-up data of ipilimumab plus nivolumab in patients with advanced renal cell carcinoma In the first article of a 2-part series.
Read More
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More